Development of a near-care diagnostic test for Lyme disease

莱姆病是北美最常见的扁虱传播疾病。新发莱姆病病例 疾病在整个加拿大都在上升，这促使人们提高了对 疾病，并对目前用于诊断的可用检测提出了问题。海流 检测依赖于在患者血液中发现的抗体的检测，这些抗体是在反应中产生的 导致莱姆病的细菌。因为这些抗体反应会随着时间的推移而发展 而且随着感染程度的不同，这项测试在诊断早期感染方面可能存在问题， 这可能会推迟抗生素的治疗。最近，人们一直在推动确定更多的 用于诊断的非抗体莱姆病标志物。这项研究将使用一种敏感的 和强大的蛋白质发现方法来挖掘血液样本以寻找新的莱姆氏标记 疾病。鉴定出的蛋白质将被用来开发一种改进的莱姆氏检测方法。 疾病。

Lyme disease is the most common tick-borne illness in North America. New cases of Lyme disease are on the rise throughout Canada, which has prompted increased awareness of the disease and raised issues with the currently available tests used for diagnosis. The current tests rely on detection of antibodies found in the patients blood that are produced in response to bacteria that cause Lyme disease. Because these antibody responses develop over time and vary with degree of infection, the test can be problematic for diagnosing early infection, which may delay antibiotic therapy. Recently, there has been a push to identify additional non-antibody Lyme disease markers for use in diagnosis. This research will use a sensitive and powerful protein discovery approach to mine blood samples for new markers of Lyme disease. The proteins identified will be used to develop an improved test for detecting Lyme disease.